Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially ...

According to their findings, semaglutide led to a "significant" reduction in overall heart weight, cardiomyocyte area, and ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

None ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...